Boris Itkin
Research Subjects
Research Interests
Boris Itkin has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Daniel Lewi
Departmento de Oncología, Hospital Dr. Juan A. Fernández
4 shared publications- Ariel Bardach
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
3 shared publications Samanta Straminsky
Affiliation Department of Oncology, Juan A Fernández Hospital, Buenos Aires, Argentina
3 shared publications- Samanta Straminsky
Departmento de Oncología, Hospital Dr. Juan A. Fernández
3 shared publications - Adolfo Marantz
Departmento de Oncología, Hospital Dr. Juan A. Fernández, Buenos Aires
2 shared publications Ariel Bardach
Affiliation Center for Research in Epidemiology and Public Health, Institute for Clinical Effectiveness and Health Policy (IECS)—National Scientific and Technical Research Council—Argentina, Buenos Aires, Argentina
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
A health-related quality of life measurement strategy for solid rare cancers: Primary findings from the EORTC Quality of Life Group (QLG) QoL Rare Cancer Study
- 14 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Open AccessA health-related quality of life measurement strategy for solid rare cancers: Primary findings from the EORTC Quality of Life Group (QLG) QoL Rare Cancer Study
- Open Access
- 18 March 2025
- Published by Spandidos Publications in Medicine International
- Vol. 5 (3) , 1-6
Next‑generation sequencing failure rates in rare tumors: A real‑world single‑institution analysis
Reported next‑generation sequencing (NGS) failure rates vary widely and are primarily based on studies of common tumor types. The present study aimed to estimate NGS failure rates in rare tumors and their association with preanalytical variables and sequencing methods in a single institution. Patients with sarcomas, rare carcinomas, and rare melanomas who underwent NGS between January 2022 and October 2023 were eligible for participation in the present study. NGS was performed as whole exome/transcriptome sequencing (WETS) based on hybrid capture or multigene commercial targeted panel. Clinicopathological and NGS‑related data were extracted from clinical charts. Univariable logistic regression models were constructed with the outcome variable NGS failure and the following explanatory variables: Assay, sampling method, tissue type , and storage time. A total of 102 NGS reports from 86 patients with sarcomas (73.3%), rare carcinomas (16.3%), and melanomas (10.5%) were included. The median age of the patients was 40 years [interquartile range (IQR), 23‑61 years]. Samples were obtained by biopsy (51%) and surgery (48%) and were collected from soft tissue (92.1%) or bone (7.9%) lesions. The median storage time was 2.5 months (IQR, 1.3‑4.6 months). Targeted panel and WETS were used in 39.2 and 60.8% of reports, respectively. NGS failure due to insufficient material quantity or quality was observed in 14.7% of tests, corresponding to 4.7% of patients. Repeated testing was successful in 7 out of 8 patients. WETS was significantly associated with a higher probability of NGS failure due to the insufficient quantity or quality of material compared to targeted panel (odds ratio, 11.4; 95% confidence interval, 1.4‑90.4; P=0.022). In summary, our findings suggest that the NGS failure rates in rare tumors are comparable to the rates reported in prevalent neoplasms. WETS can be associated with more frequent NGS failure than targeted panel. Retesting can often overcome the initial NGS testing failure.
- 18 March 2025
- Published by Spandidos Publications in Medicine International
- Vol. 5 (3) , 1-6
Open AccessNext‑generation sequencing failure rates in rare tumors: A real‑world single‑institution analysis
Reported next‑generation sequencing (NGS) failure rates vary widely and are primarily based on studies of common tumor types. The present study aimed to estimate NGS failure rates in rare tumors and their association with preanalytical variables and sequencing methods in a single institution. Patients with sarcomas, rare carcinomas, and rare melanomas who underwent NGS between January 2022 and October 2023 were eligible for participation in the present study. NGS was performed as whole exome/transcriptome sequencing (WETS) based on hybrid capture or multigene commercial targeted panel. Clinicopathological and NGS‑related data were extracted from clinical charts. Univariable logistic regression models were constructed with the outcome variable NGS failure and the following explanatory variables: Assay, sampling method, tissue type , and storage time. A total of 102 NGS reports from 86 patients with sarcomas (73.3%), rare carcinomas (16.3%), and melanomas (10.5%) were included. The median age of the patients was 40 years [interquartile range (IQR), 23‑61 years]. Samples were obtained by biopsy (51%) and surgery (48%) and were collected from soft tissue (92.1%) or bone (7.9%) lesions. The median storage time was 2.5 months (IQR, 1.3‑4.6 months). Targeted panel and WETS were used in 39.2 and 60.8% of reports, respectively. NGS failure due to insufficient material quantity or quality was observed in 14.7% of tests, corresponding to 4.7% of patients. Repeated testing was successful in 7 out of 8 patients. WETS was significantly associated with a higher probability of NGS failure due to the insufficient quantity or quality of material compared to targeted panel (odds ratio, 11.4; 95% confidence interval, 1.4‑90.4; P=0.022). In summary, our findings suggest that the NGS failure rates in rare tumors are comparable to the rates reported in prevalent neoplasms. WETS can be associated with more frequent NGS failure than targeted panel. Retesting can often overcome the initial NGS testing failure.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Cancer Research, Statistics, and Treatment
- Vol. 7 (4) , 483-484
Biology or methodology?
- 1 October 2024
- Published by Wolters Kluwer Health in Cancer Research, Statistics, and Treatment
- Vol. 7 (4) , 483-484
Open AccessBiology or methodology?
- Open Access
- 15 June 2024
- Published by Elsevier in IJID Regions
- Vol. 12, 100389
Predominance of Candida glabrata in candidemia among patients with solid tumor cancer in Oman: A retrospective study
- 15 June 2024
- Published by Elsevier in IJID Regions
- Vol. 12, 100389
Open AccessPredominance of Candida glabrata in candidemia among patients with solid tumor cancer in Oman: A retrospective study
- Open Access
- 30 June 2023
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 40 (2) , 161-9
Comparison of mortality in patients on chemotherapy or immunotherapy during and before the COVID-19 pandemic. Multicenter matched cohort study in Argentina
Objectives. To compare the mortality of unvaccinated oncology patients who received chemotherapy or immunotherapy during the pandemic with those treated before the pandemic. Materials and methods. We conducted a cohort study in four tertiary hospitals in Argentina. Outpatients with a solid neoplasm of any stage on cytotoxic or intravenous immune therapy were eligible. The pandemic cohort was enrolled during the initial phase of the outbreak and compared with a cohort from a pre-pandemic period using propensity score matching (PSM). Subjects were matched for age, sex, health insurance, severe COVID-19 complications risk, performance status, cancer and treatment type, treatment line, and body mass index. All-cause mortality was estimated in both cohorts after the 6-month follow-up. Results. Out of 169 patients recruited between April and August 2020 to the pandemic and 377 to the pre-pandemic cohorts in the same period of 2019, 168 were matched. After PSM, all-cause mortality was 17.9% in the pandemic and 18.5% in the pre-pandemic cohort, Risk Ratio: 0.97 (95% confidence interval: 0.61-1.52, p=0.888). In the pandemic cohort, 30/168 patients died - none of them from COVID-19 infection. Conclusions. We failed to demonstrate an increment in the mortality of unvaccinated, ambulatory patients on active intravenous anticancer treatment exposed to the COVID-19 pandemic.
- 30 June 2023
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 40 (2) , 161-9
Open AccessComparison of mortality in patients on chemotherapy or immunotherapy during and before the COVID-19 pandemic. Multicenter matched cohort study in Argentina
Objectives. To compare the mortality of unvaccinated oncology patients who received chemotherapy or immunotherapy during the pandemic with those treated before the pandemic. Materials and methods. We conducted a cohort study in four tertiary hospitals in Argentina. Outpatients with a solid neoplasm of any stage on cytotoxic or intravenous immune therapy were eligible. The pandemic cohort was enrolled during the initial phase of the outbreak and compared with a cohort from a pre-pandemic period using propensity score matching (PSM). Subjects were matched for age, sex, health insurance, severe COVID-19 complications risk, performance status, cancer and treatment type, treatment line, and body mass index. All-cause mortality was estimated in both cohorts after the 6-month follow-up. Results. Out of 169 patients recruited between April and August 2020 to the pandemic and 377 to the pre-pandemic cohorts in the same period of 2019, 168 were matched. After PSM, all-cause mortality was 17.9% in the pandemic and 18.5% in the pre-pandemic cohort, Risk Ratio: 0.97 (95% confidence interval: 0.61-1.52, p=0.888). In the pandemic cohort, 30/168 patients died - none of them from COVID-19 infection. Conclusions. We failed to demonstrate an increment in the mortality of unvaccinated, ambulatory patients on active intravenous anticancer treatment exposed to the COVID-19 pandemic.
- Open Access
- 30 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257976
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2= 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2= 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2= 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2= 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
- 30 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257976
Open AccessPrevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2= 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2= 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2= 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2= 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
- Open Access
- 1 March 2021
- Published by Springer Nature in Research Square
Prevalence of HER2 overexpression and amplification in uterine cervical cancer: a systematic review and a meta-analysis.
BackgroundThe reported rates of HER2 positivity in uterine cervical cancer (CC) range from 0–87%. The organization of clinical studies of HER2 targeting agents in CC requires a better knowledge of HER2 positivity prevalence. We aimed to provide precise estimates of HER2 overexpression and amplification in CC.MethodsWe conducted a PRISMA compliant meta-analytic systematic review. We searched electronic databases for articles reporting the proportion of HER2 positivity by immunohistochemistry or in situ hybridization in CC. We performed descriptive analyses of all 65 included studies. Of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators.ResultsThe estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5–11.7%) in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9–34.8%) in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0–5.8%) and 24.9% (CI 95%: 12.6–39.6%), respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates.ConclusionA small proportion of CC is expected to be HER2 positive. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
- 1 March 2021
- Published by Springer Nature in Research Square
Open AccessPrevalence of HER2 overexpression and amplification in uterine cervical cancer: a systematic review and a meta-analysis.
BackgroundThe reported rates of HER2 positivity in uterine cervical cancer (CC) range from 0–87%. The organization of clinical studies of HER2 targeting agents in CC requires a better knowledge of HER2 positivity prevalence. We aimed to provide precise estimates of HER2 overexpression and amplification in CC.MethodsWe conducted a PRISMA compliant meta-analytic systematic review. We searched electronic databases for articles reporting the proportion of HER2 positivity by immunohistochemistry or in situ hybridization in CC. We performed descriptive analyses of all 65 included studies. Of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators.ResultsThe estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5–11.7%) in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9–34.8%) in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0–5.8%) and 24.9% (CI 95%: 12.6–39.6%), respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates.ConclusionA small proportion of CC is expected to be HER2 positive. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
- Open Access
- 18 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3551
New Treatments in Renal Cancer: The AhR Ligands
Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.
- 18 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3551
Open AccessNew Treatments in Renal Cancer: The AhR Ligands
Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.
- Open Access
- 15 August 2019
- Published by Asociacion Argentina de Oncologia Clinica in Oncología Clínica
- Vol. 24 (2)
Cambios cuantitativos en el nivel de expresión de los receptores hormonales en pacientes con cáncer de mama
Si bien se estudió ampliamente la discordancia de los receptores hormonales en la evolución del cáncer de mama, casi siempre se trató como una variable dicotómica, sin tener en cuenta sus valores absolutos. El grado, la dirección y la importancia de las variaciones cuantitativas en el tiempo en el nivel de expresión de los receptores de estrógeno (RE) y los receptores de progesterona (RP) son en gran parte desconocidos. Realizamos un análisis retrospectivo de los cambios cuantitativos en el nivel de RE y RP en muestras pareadas de lesiones primarias o recurrentes del mismo paciente en dos puntos separados en el tiempo. La expresión de RE y d RP se registró como el porcentaje de células teñidas. Los análisis de subgrupos no fueron planificados previamente. Se incluyeron 68 mujeres con cáncer de mama de cualquier estadio. La prueba de rango con signo de Wilcoxon indicó una reducción estadísticamente significativa en la expresión de RE entre la primera y la segunda determinación de RE (Z=-2.75, r=-0.23, p=0.006). Para RP, la diferencia no fue estadísticamente significativa. En los análisis de subgrupos, después de la corrección de Bonferroni, sólo la exposición al tratamiento endocrino, el tejido obtenido mediante cirugía y la edad >40 años se asociaron significativamente con la disminución en el nivel de expresión de RE. A pesar de que el error aleatorio y los problemas técnicos son probablemente las principales fuentes de la variabilidad de la RE, los resultados de nuestro estudio sugieren una tendencia a una disminución en la expresión de la RE, en la relación con la metodología de muestreo de tejidos y/o la exposición a la terapia endocrina.
- 15 August 2019
- Published by Asociacion Argentina de Oncologia Clinica in Oncología Clínica
- Vol. 24 (2)
Open AccessCambios cuantitativos en el nivel de expresión de los receptores hormonales en pacientes con cáncer de mama
Si bien se estudió ampliamente la discordancia de los receptores hormonales en la evolución del cáncer de mama, casi siempre se trató como una variable dicotómica, sin tener en cuenta sus valores absolutos. El grado, la dirección y la importancia de las variaciones cuantitativas en el tiempo en el nivel de expresión de los receptores de estrógeno (RE) y los receptores de progesterona (RP) son en gran parte desconocidos. Realizamos un análisis retrospectivo de los cambios cuantitativos en el nivel de RE y RP en muestras pareadas de lesiones primarias o recurrentes del mismo paciente en dos puntos separados en el tiempo. La expresión de RE y d RP se registró como el porcentaje de células teñidas. Los análisis de subgrupos no fueron planificados previamente. Se incluyeron 68 mujeres con cáncer de mama de cualquier estadio. La prueba de rango con signo de Wilcoxon indicó una reducción estadísticamente significativa en la expresión de RE entre la primera y la segunda determinación de RE (Z=-2.75, r=-0.23, p=0.006). Para RP, la diferencia no fue estadísticamente significativa. En los análisis de subgrupos, después de la corrección de Bonferroni, sólo la exposición al tratamiento endocrino, el tejido obtenido mediante cirugía y la edad >40 años se asociaron significativamente con la disminución en el nivel de expresión de RE. A pesar de que el error aleatorio y los problemas técnicos son probablemente las principales fuentes de la variabilidad de la RE, los resultados de nuestro estudio sugieren una tendencia a una disminución en la expresión de la RE, en la relación con la metodología de muestreo de tejidos y/o la exposición a la terapia endocrina.
- 5 May 2018
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 48 (7) , 640-652
Prognosis of metastatic giant cell tumor of bone in the pre-denosumab era. A systematic review and a meta-analysis
Data on long-term prognosis of metastatic GCT (mGCT) is scant. The frequency of spontaneous regressions (SRs) is unknown. We aimed to estimate the prognosis of mGCT. We searched electronic scientific literature databases and generic Internet from January 1980 to August 2017. After identifying eligible studies we performed descriptive analyses and meta-analyses to estimate overall survival (OS), disease specific survival (DSS) and frequency of SRs in the years before the widespread use of denosumab. We performed pre-specified subgroup analyses of studies published before and after 2000 and of those with more and less than 10 years of follow-up. After retrieving and combining data from 26 relevant retrospective case-series totaling 242 patients with a median follow-up of 6.9 years, the estimated pooled OS was 86.9% (95% CI 78.0-94.2). Pooled DSS was 88.0% (95% CI 79.7-94.7). SRs were observed in 4.5% of patients. In the subgroup of studies published after 2000 mGCT was the only cause of death of affected subjects. In case-series with a follow-up longer than 10 years pooled DSS was 69.7% (95% CI 25.5-99.8). To our knowledge this is the first study to derive estimated pooled OS and DSS of mGCT based on a large dataset. SRs were not exceptional phenomena. In a long run the disease could impact in a significant way on the life expectancy of affected subjects.
- 5 May 2018
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 48 (7) , 640-652
Prognosis of metastatic giant cell tumor of bone in the pre-denosumab era. A systematic review and a meta-analysis
Data on long-term prognosis of metastatic GCT (mGCT) is scant. The frequency of spontaneous regressions (SRs) is unknown. We aimed to estimate the prognosis of mGCT. We searched electronic scientific literature databases and generic Internet from January 1980 to August 2017. After identifying eligible studies we performed descriptive analyses and meta-analyses to estimate overall survival (OS), disease specific survival (DSS) and frequency of SRs in the years before the widespread use of denosumab. We performed pre-specified subgroup analyses of studies published before and after 2000 and of those with more and less than 10 years of follow-up. After retrieving and combining data from 26 relevant retrospective case-series totaling 242 patients with a median follow-up of 6.9 years, the estimated pooled OS was 86.9% (95% CI 78.0-94.2). Pooled DSS was 88.0% (95% CI 79.7-94.7). SRs were observed in 4.5% of patients. In the subgroup of studies published after 2000 mGCT was the only cause of death of affected subjects. In case-series with a follow-up longer than 10 years pooled DSS was 69.7% (95% CI 25.5-99.8). To our knowledge this is the first study to derive estimated pooled OS and DSS of mGCT based on a large dataset. SRs were not exceptional phenomena. In a long run the disease could impact in a significant way on the life expectancy of affected subjects.